IDH 305

Drug Profile

IDH 305

Alternative Names: IDH305

Latest Information Update: 03 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Novartis; Novartis Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Solid tumours

Most Recent Events

  • 04 Oct 2017 Novartis and New York University School of Medicine plans a phase II trial for Glioma in USA, in April 2018 (NCT02977689)
  • 05 Dec 2016 University of Texas Southwestern Medical Center plans a phase II trial for Glioma (Neoadjuvant therapy, Inoperable/Unresectable) in USA (PO) (NCT02987010)
  • 03 Dec 2016 Efficacy and adverse events data from a phase I trial in Solid tumours presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top